Endpoints News 28 janv. 2026 HHS seeks to protect drugmakers from anti-kickback laws ahead of TrumpRx launch
Endpoints News 28 janv. 2026 Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data
Endpoints News 27 janv. 2026 CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
Endpoints News 27 janv. 2026 Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma